NuGenea is a subsidiary of Ludwig Enterprises, Inc is a healthcare holding company that is blazing a new trail in healthcare utilizing the body’s own language, mRNA, to measure and monitor critical biomarkers of chronic inflammation. Ludwig’s cutting-edge science may lead to the development of personalized therapeutics targeting illnesses such as cancer, diabetes, COPD and heart disease, which lead to more than 50% of the world’s deaths according to World Health Organization statistics.

A Public Company, Ludwig (OTC:LUDG) is traded over the counter in the United States and on the Canadian Stock Exchange (CSE).  We welcome investments of any size.  If interested please click on the link below to view our investor website and learn more.